Use of Nasal Nitric Oxide Testing in Improving Primary Ciliary Dyskinesia Clinical Care

Arkansas Children's Hospital Research Institute (Other)
Overall Status
Recruiting ID

Study Details

Study Description

Brief Summary

this study is aiming at learning more about primary ciliary dyskinesia (PCD) and tests that are used to diagnose this condition. One purpose of this study is to measure the level of nitric oxide in the nasal passages and examine how often the results correlate with other tests currently done to make the diagnosis.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    This will be an observational study. Participants who are referred by their clinician for nasal NO testing and meet the inclusion and exclusion criteria will be allowed to undergo testing. Informed consent will be completed prior to testing. The participant and/or guardian will be informed that this testing is not a clinically approved test at this time and thus it cannot confirm diagnosis of PCD. This test is to correlate with other diagnostic tests so that in the future it can be an approved diagnostic test. Data will be collected from the electronic medical records regarding participants.

    The data collected will be stored on a REDCap (Research Electronic Data Capture) registry. The registry will contain participants' direct identifiers (like medical record). De-identified data will be used from the registry for monitoring, further analysis and presentations. The results of the testing may be included in the medical chart of each participant as part of the diagnosis discussion with family.

    Consent forms will be obtained from participants >18 years of age or who are emancipated minors, or guardian for patients <18 years of age. Guardian refers to parent, guardian, or legally authorized personnel throughout this document.

    The data collected will be used to refine and improve the diagnostic testing for PCD at Arkansas Children's Hospital. This will also involve collaboration with other sub-specialties like otolaryngology and allergy/immunology. With continued research regarding nasal nitric oxide testing, this may involve the use of this test as a screening tool for PCD in the right clinical setting. This will involve analyzing the association of nasal nitric oxide levels with approved diagnostic tests (ciliary biopsy and genetic testing).

    Testing will be completed using (Eco-Physics Analyzer CLD 88 sp with DENOX 88). this testing will be done in the Arkansas Children's hospital pulmonary function laboratory, once all training is completed.

    This equipment is not currently FDA approved for PCD diagnostic testing and therefore, referring clinicians will be informed of the results of this test and its limitations as a research tool will be discussed. However, there is growing evidence that this testing has utility as a non-invasive screening tool for PCD and continued data from the general pediatric pulmonary population is needed.

    In addition to being non-invasive testing, it has very little risk as it simply monitors nasal nitric oxide levels in the sinus cavities during regular breathing without sedation. There is ongoing research to better determine normative values and thresholds for further PCD confirmatory testing, especially in the younger population. In the general population this testing has a greater negative predictive value than a positive predictive value. Consequently, the testing will be done on individuals who have at least two of the following clinical criteria for PCD: history of neonatal respiratory distress, chronic rhinitis, chronic cough, or situs defects.

    Study Design

    Study Type:
    Anticipated Enrollment :
    150 participants
    Observational Model:
    Time Perspective:
    Official Title:
    Use of Nasal Nitric Oxide Testing in Improving Primary Ciliary Dyskinesia Clinical Care
    Actual Study Start Date :
    Jun 14, 2021
    Anticipated Primary Completion Date :
    Jun 1, 2024
    Anticipated Study Completion Date :
    Jun 1, 2025

    Outcome Measures

    Primary Outcome Measures

    1. Measuring nasal nitric oxide in comparison to ciliary biopsy and genetic testing for the diagnosis of PCD [throughout the study, an average of 3 years]

      Individuals with PCD have characteristically low values of nNO; values below an established cut-off of 77nL/min are strongly associated with PCD in compatible clinical settings. These values are not well established for individuals who are in 2-5 years of age. nNO measurements (in nL/min) in 2-5 years of age will be compared to the diagnosis of PCD and assessed to establish diagnostic cut-offs.

    Secondary Outcome Measures

    1. Comparing tidal breathing to resistor method [throughout the study, an average of 3 years]

      comparing nNO values in nL/min obtained via tidal breathing technique to those obtained via resistor method.

    Eligibility Criteria


    Ages Eligible for Study:
    2 Years to 21 Years
    Sexes Eligible for Study:
    Accepts Healthy Volunteers:
    Inclusion Criteria:
    • • Individuals who are diagnosed with Primary Ciliary Dyskinesia OR

    • Individuals undergoing PCD diagnostic testing (ciliary biopsy, PCD genetic testing) or concern based on clinical symptoms (at least two of the following):

    • Neonatal respiratory distress

    • Organ laterality defects

    • Year-round cough starting in first year of life or bronchiectasis on chest CT

    • Year-round nasal congestion starting in first year of life or pansinusitis

    • Multiple ear infections in the first two years of life with sequelae (e.g. ear tubes, chronic effusion, abnormal audiological exam)

    • Ability to provide consent for participation in study by the participants or guardian

    • Ability to perform the test

    • Age >= 2 years of age

    Exclusion Criteria:
    • • Individuals who are unable to understand the requirements of the study.

    • Individuals (or guardians) who are unwilling to provide consent.

    • Individuals who are unable to complete the testing

    • Recent history of sinus surgery (within four weeks) or bloody nose (within one week) of testing (they can be included at a later date)

    • Patients who are currently being treated (within one week) with antibiotics for sinusitis or respiratory symptoms (they can be included at a later date)

    • Age <2 years of age

    Contacts and Locations


    Site City State Country Postal Code
    1 Arkansas Children's Hospital Little Rock Arkansas United States 72202

    Sponsors and Collaborators

    • Arkansas Children's Hospital Research Institute


    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information


    Responsible Party:
    Arkansas Children's Hospital Research Institute Identifier:
    Other Study ID Numbers:
    • 260432
    First Posted:
    Mar 18, 2022
    Last Update Posted:
    Mar 18, 2022
    Last Verified:
    Mar 1, 2022
    Studies a U.S. FDA-regulated Drug Product:
    Studies a U.S. FDA-regulated Device Product:
    Keywords provided by Arkansas Children's Hospital Research Institute
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 18, 2022